DNA Synthesis Market Size, Share, Trends, Growth and Forecast 2026–2034

DNA Synthesis Market Overview Analysis by Fortune Business Insights

Market Summary

According to Fortune Business Insights: The global DNA synthesis market size was valued at USD 5.19 billion in 2025 and is projected to grow from USD 5.95 billion in 2026 to USD 24.06 billion by 2034, exhibiting a compound annual growth rate (CAGR) of 19.09% during the forecast period. North America dominated the market with a 54.61% share in 2025, reflecting the region's advanced research infrastructure, strong healthcare spending, and concentration of leading industry players.

DNA synthesis refers to the artificial manufacture of deoxyribonucleic acid (DNA). The ability to construct synthetic DNA — including oligonucleotides, genes, and DNA fragments — has transformed biological research and medicine. Synthetic DNA is utilized in drug and vaccine development, gene therapies for genetic disorders, and the creation of molecular diagnostic tools such as PCR assays and nucleic-acid-based sensors for detecting pathogens and diseases.

Get a Sample Research PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/109799

Key Market Drivers

The most significant driver is the growing demand for synthetic DNA products and services across therapeutics, diagnostics, and research. Rising prevalence of chronic, genetic, and rare diseases — combined with heightened awareness of personalized medicine — has intensified the need for precise, customizable DNA solutions. For instance, an estimated 2,001,140 new cancer cases were projected in the U.S. in 2024 alone, amplifying demand for early and accurate molecular diagnostics that rely on synthesized oligonucleotides as probes and primers.

Regulatory approvals for gene-based therapies are further accelerating market expansion. The U.S. FDA's December 2023 approval of Casgevy and Lyfgenia — the first cell-based gene therapies for sickle cell disease — underscored the growing clinical validation of synthetic DNA in therapeutic applications. Increasing healthcare expenditure focused on precision medicine is also fueling the market; for example, the U.K. government committed to increasing public R&D spending by USD 27.36 billion by 2025, with a portion dedicated to precision medicine initiatives.

Technological advancements are reshaping the synthesis landscape. Microfluidics-based synthesis approaches dramatically reduce turnaround times through automated, parallelized reactions, while enzymatic DNA synthesis methods are gaining traction for their sustainability and accuracy. Key players are actively investing in reducing the cost of synthetic DNA, making it more accessible for large-scale research and commercial use.

Key Market Restraints

The primary restraint is the absence of a robust and harmonized regulatory framework for synthetic DNA products and services. Regulatory uncertainty slows the commercialization of new synthesis services, particularly for oligonucleotide-based therapeutics. In September 2022, the European Medicines Agency released a concept paper proposing guidelines on the development and manufacture of synthetic oligonucleotides, underscoring that clear standards are still evolving. A shortage of skilled laboratory personnel capable of operating advanced DNA synthesis platforms and interpreting outputs also limits market scalability, particularly in emerging economies.

Market Segmentation

By product and service, the services segment commanded a dominant 72.76% share in 2026. DNA synthesis service providers offer comprehensive, high-purity, cost-effective, and customizable solutions with faster turnaround times, making them attractive to pharmaceutical companies and academic research institutes alike. Within the products segment, reagents and consumables account for the largest share, given their broad application in diagnostics and therapeutics. Notable recent activities include Asahi Kasei Bioprocess's collaboration with Axolabs in April 2024 to launch a cGMP oligonucleotide manufacturing facility in Germany.

By type, the gene synthesis segment holds the dominant share of 74.31% in 2026, driven by advances in synthesis technology that have reduced costs and enabled highly customizable DNA sequences to meet diverse research and industrial needs. Twist Bioscience's November 2023 launch of its Twist Express Genes service — offering genes from 0.3 to 5.0 kb with five-to-seven-day turnaround — exemplifies the growing push for speed and flexibility in this space. The oligonucleotide synthesis segment holds a considerable share, supported by rising demand from molecular diagnostics, therapeutics, and vaccine development.

By application, the diagnostics segment led the global market with a projected 50.26% share in 2026, supported by the widespread use of synthesized oligonucleotides in PCR-based diagnostics and the growing incidence of infectious diseases and cancer worldwide. The therapeutics segment is also expanding rapidly, fueled by increasing regulatory approvals for gene and cell therapies, including Pfizer's April 2024 FDA approval of BEQVEZ for hemophilia B treatment. The research and development segment is growing steadily, driven by advancing drug discovery, gene cloning, editing, and synthetic biology initiatives.

By end-user, pharmaceutical and biotechnology companies dominated in 2024, reflecting their active investment in synthetic DNA for novel drug and therapy development. Contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) hold a significant share, given their advanced infrastructure, regulatory expertise, and capacity for large-scale custom DNA production.

Regional Outlook

North America generated USD 2.83 billion in 2025 and is projected to reach USD 3.22 billion in 2026, with the U.S. alone projected at USD 3.03 billion by 2026. The region benefits from advanced research facilities, active fundraising, and a large pipeline of gene therapy candidates.

Europe contributed USD 1.14 billion in 2025 — a 22.06% share — and is expected to reach USD 1.33 billion in 2026, driven by growing R&D activity and strategic collaborations between industry and academia. Germany (USD 0.32 billion by 2026) and the U.K. (USD 0.22 billion by 2026) are the leading national markets.

Asia Pacific accounted for USD 0.88 billion in 2025 and is projected to grow at the highest regional CAGR through 2034, supported by expanding healthcare infrastructure, rising investment in DNA manufacturing facilities, and increasing industry partnerships. China, Japan, and India are projected to reach USD 0.43 billion, USD 0.24 billion, and USD 0.13 billion, respectively, by 2026. Latin America and the Middle East and Africa contribute smaller shares but are expected to see moderate growth as governments increase biotechnology investment and infrastructure.

Connect with Our Expert for any Queries: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/109799

Competitive Landscape

The market features a semi-consolidated structure. Leading players include Thermo Fisher Scientific, Integrated DNA Technologies (Danaher), GenScript, Eurofins Scientific, Twist Bioscience, Azenta, LGC Limited, Telesis Bio, Biomatik, and Bioneer Corporation. Competition centers on service quality, turnaround speed, cost reduction, and customization capabilities. Strategic expansion of manufacturing capacity — such as GenScript's 2023 Singapore facility launch and its GenTitan semiconductor-based high-throughput synthesis platform — illustrates the industry's focus on scaling access to synthetic DNA globally.